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This issue of the Journal features the comprehensive meta-
analysis of 12 putative sudden cardiac death (SCD) risk
stratiﬁcation tests for patients with nonischemic dilated
cardiomyopathy (NIDCM) by Goldberger et al. (1).
Although the exact incidence remains elusive (1), SCD is
clearly common and NIDCM is the second largest cause
behind ischemic heart disease. Compared with ischemic
patients, NIDCM patients are younger (averaging 52.8 years
in the meta-analysis), possess fewer comorbidities, and thus
a lower competing mortality risk supporting their candidacy
for an implantable cardiac deﬁbrillator (ICD) to reduce
SCD. An ICD is indicated for low ejection fraction (EF)
patients on the basis of several large clinical trials demon-
strating reduction in total mortality (2–4). Nevertheless,See page 1879likely stemming from a lower mortality rate, NIDCM
patients have less deﬁnitive evidence supporting an ICD
indication. Speciﬁcally, the DEFINITE (Deﬁbrillators In
Non-Ischemic Cardiomyopathy Treatment Evaluation)
trial, the largest NIDCM-only ICD trial yielded a border-
line statistically signiﬁcant reduction in mortality (3). Ulti-
mately, though, a meta-analysis of ICDs in NIDCM found
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this paper to disclose.MADIT–RIT (Multicenter Automatic Deﬁbrillator Im-
plantation Trial–Reduce Inappropriate Therapy) study
suggests that suboptimal programming resulting in unnec-
essary and/or inappropriate shocks may have obscured
potentially greater ICD mortality beneﬁt (6).
Owing to those clinical trials (2–4), EF dominates ICD
indication determination. However, EF is neither a sensitive
nor a speciﬁc SCD risk marker. Two-thirds of sudden cardiac
arrests in a community-based registry occurred in patients
with an EF >35% (7). Similarly, only one-third of patients
with an EF <35% experienced an ICD discharge 3 years
after enrollment in MADIT II (8). These facts illustrate the
elusive attraction of improved SCD risk stratiﬁcation.
Against this backdrop, Goldberger et al. (1) reviewed 45
publications encompassing 6,088 patients. Risk markers were
categorized as follows: 1) autonomic parameters (baroreﬂex
sensitivity, heart rate turbulence, and heart rate variability);
2) left ventricular structural measures (end-diastolic dimen-
sion and EF); 3) arrhythmia-related (nonsustained ventricular
tachycardia and inducibility); 4) ventricular depolarization
measures (QRS duration, left bundle branch block, QRS
fragmentation, and signal-averaged electrocardiography); and
5) repolarization (T-wave alternans). Adjusting for possible
publication bias using funnel plot analysis (1), the observed
risk for most of these tests was 1.5 to 3.0, too low,
the researchers acknowledge, to be used individually for
ICD allocation or denial. The QRS fragmentation looked
promising but only 2 studies were available. Interestingly,
autonomic parameters performed poorly, despite prior
mechanistic studies linking the autonomic nervous system
and life-threatening arrhythmias (9,10). Of note, the negative
early post-myocardial infarction ICD trials (11,12) included
autonomic entry criteria (counting elevated heart rate as a
marker of low vagal and/or high sympathetic tone) (12).
Although comprehensive and conducted by experts in the
ﬁeld, several limitations of this meta-analysis exist. First, the
meta-analysis constitutive studies were generally small, and
of modest quality; furthermore, many patients did not
receive contemporary, optimal medical therapy. Second, as
acknowledged by the investigators, there is a high likelihood
of publication bias, namely, nonpublication of negative data,
overinﬂating our impression of some tests. Third, comparing
risk stratiﬁcation tests on the basis of disparate trials is
inherently unfair. Nevertheless, this meta-analysis is likely
the best data available. Fourth, the primary studies’ endpoints
varied from arrhythmic deaths to ICD events. Fifth, ICD
shocks are a poor surrogate for sudden cardiac death events
(13), greatly overestimating life-threatening arrhythmia
occurrence. The recent MADIT–RIT study further
emphasized the reality that many ventricular arrhythmias that
have been treated by ICDs would have self-terminated.
Although ICD events are imperfect as a surrogate for sud-
den death, even sudden cardiac death is not synonymous
with an arrhythmic death preventable by an ICD. In the
VALIANT (VALsartan In Acute myocardial iNfarcTion)
trial, albeit an ischemic heart disease study, many of the early
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rupture rather than ventricular ﬁbrillation (14).
Arrhythmia mechanisms operative in NIDCM are
incompletely understood (1), and may be multifactorial.
Delayed hyperenhancement on magnetic resonance imaging,
not included in the meta-analysis, may predict arrhythmic
events in NIDCM (15). The association of serious ventric-
ular arrhythmias with scar detected by magnetic resonance
imaging highlights macroreentry as the predominant
arrhythmia mechanism, as in ischemic cardiomyopathy (15).
Moving forward, how do we improve identiﬁcation of
patients for an ICD, advance risk stratiﬁcation, and verify
some of the conclusions reached by Goldberger et al. (1)?
Implicit in NIDCM risk stratiﬁcation is the concept of
foregoing ICDs for some currently indicated patients.
Clearly, ethical challenges in conducting such clinical trials
exist. Can we count on the absence of these risk factors for
identifying patients who are free of risk? The long-term
follow-up of the MADIT-II study would suggest that
caution is warranted. Initially, it appeared that patients
lacking several risk markers could thrive without ICD (16).
However, extended follow-up revealed that these “low-risk”
patients eventually demonstrated ICD beneﬁt (17). Patients
at low risk of heart failure death having few competing risks
might be better ICD candidates in the long run than severe
heart failure patients with high non–sudden death risk. The
estimated sample size (n z 17,000) of a trial seeking to
prove noninferiority of nonimplantation in low-risk
NIDCM patients may be prohibitive (18), and if conduct-
ed, should be of ample duration (17). In conclusion, this
meta-analysis updates our knowledge base and emphasizes
that further basic and clinical research is critical to cost-
effective reduction of SCD in NIDCM in the hope of
making risk stratiﬁcation for SCD less mythical.
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